Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD for early-stage dementia
ACTRN12621001364864Phase 2Terminated
- Sponsor
- University of Wollongong
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Dementia comparing Cannabidiol with Placebo (2 arms). Primary endpoints: Change in brain structure, Change in white matter connectivity and 1 more. Started Aug 2022; status: terminated.
02
Drugs
cannabidiol
03
Conditions
Dementia
Beyond the preview
Go deeper on ACTRN12621001364864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001364864.